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Systemic Mastocytosis
Ioannis Markou, MD1, Maria Pagoni, MD1, Theodoros Tegos, MD2,  
George Andreou, MD3, Dimitra Rontogianni, MD3,  
Nicolaos Harhalakis, MD1
A 64-year-old man was admitted to the Hematology ward in July 2012 due to 
neutropenia and thrombocytopenia. The only symptom in the month preceding his 
admission was significant weight loss. Based on clinical and laboratory investigations, 
specifically bone marrow aspiration and biopsy (Figure), the patient was diagnosed 
with aggressive systemic mastocytosis (WHO 2008 ICD-0 code 9741/3).
The patient initially received treatment with cladribine 8.5 mg once daily in 2-hour 
intravenous infusion for a 5-day period/28-day cycle. Following the completion of a 
5-cycle treatment course with cladribine, thrombocytopenia improved, but there was 
no significant change in neutropenia, while the hematocrit remained stable. However, 
the patient did not show any clinical improvement. Thus, he was reevaluated with bone 
marrow biopsy, which showed 40% infiltration by malignant mast cells. There was 
underlying disease of myeloblastic/myeloproliferative neoplasm unclassifiable with 3% 
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FIGurE. Mast cells (arrows) show abundant purple granules and oval to spindle nuclei in 
contrast to round and reniform normal nuclei.
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CD34 positive myeloblasts (systemic mastocytosis associated 
hematological non-mast cell disorder - SM-AHNMD).
The patient was considered refractory to cladribine, 
therefore it was decided to administer standard acute my-
eloid leukemia chemotherapy induction with a 7-day course 
of cytarabine 100 mg/m2 continuous infusion and idarubicin 
12 mg/m2 for 3 days followed by a second cycle with 5 days 
cytarabine infusion and 2 days idarubicin. The patient experi-
enced prolonged aplasia after each chemotherapy cycle and his 
course was complicated by severe pneumonia which required 
hospitalization for several weeks. There was no hematologic 
improvement and the bone marrow biopsy showed persistent 
infiltration by malignant mast cells (30%) and presence of 
2-3% myeloblasts (SM-AHNMD).
Because of the poor response to standard chemotherapy, 
the patient was offered investigational treatment with dasat-
inib. He received dasatinib 100 mg once daily for a 4-month 
period. The patient initially seemed to respond to the new 
therapy, albeit at the expense of significant side-effects. How-
ever, soon afterwards his clinical condition worsened and this 
treatment was discontinued. Treatment plan was subsequently 
changed to a trial of interferon-alpha (IFN-α). The starting 
dose of IFN-α was 3×106×3/week and it was gradually in-
creased to IFN-α 4.5×106×5/week. The patient tolerated IFN-α 
relatively well, and this time he showed clinical improvement, 
having regained his appetite and putting on weight. However, 
the patient experienced treatment related hematologic toxicity, 
especially thrombocytopenia while he remained transfusion 
independent. Nevertheless, a hematologic improvement was 
confirmed on blood smear examination, pending reassessment 
with a new bone marrow biopsy.
●●●
Systemic mastocytosis is a rare disease, characterized as 
a myeloproliferative neoplasm coming from clonal prolifera-
tion of abnormal mast cells in one or more extra-cutaneous 
organs.1-8 Presence of multifocal clusters of morphologically 
abnormal mast cells in the bone marrow is considered as the 
major criterion.2 Minor diagnostic criteria comprise elevated 
serum tryptase level, abnormal mast cell expression of CD25 
and/or CD2, and presence of the KIT mutation D816V. At 
least one major and one minor or at least 3 minor criteria 
have to be fulfilled to establish the diagnosis of systemic 
mastocytosis.
Systemic mastocytosis is a progressive neoplastic disorder 
that has no known curative therapy, except perhaps for alloge-
neic hematopoietic stem-cell transplantation, which may turn 
out to be a viable therapeutic option.9 It is classified as indolent 
mastocytosis, with no organ dysfunction and a good prognosis, 
mastocytosis associated with other hematologic disorders (SM-
AHNMD), aggressive mastocytosis, characterized by impaired 
organ function, and mast cell leukemia, with >20% mast cells 
in the bone marrow, no skin lesions, multi-organ failure, and 
a poor prognosis.2
Several antineoplastic drugs and approaches have been 
employed for the treatment of patients with aggressive sys-
temic mastocytosis and mast cell leukemia, some based on 
the inhibition of KIT D816V in neoplastic cells.1-4,7,8 However, 
results remain unsatisfactory and treatment of advanced 
systemic mastocytosis remains one of the most challenging 
areas in clinical hematology. Even combined chemotherapy 
and hematopoietic stem cell transplantation may fail, which 
dictates the need to develop new drugs and treatment schemes 
and approaches for these patients.9
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